The tumor types we’re focused on are lung, breast and malignant heme. We also have a strong emphasis on colorectal cancer, because there have been more and more cases of earlier diagnosed colorectal ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own ...
Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell ...
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic ...
London, UK – May 05, 2026. Cytospire Therapeutics (‘Cytospire’), a UK based biotech developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity ...
Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results